| Year |
Citation |
Score |
| 2023 |
Brock P, Sévigny M, Liyanarachchi S, Comiskey DF, Li W, Saarinen S, Yilmaz AS, Nieminen AII, Ringel MD, Peltomaki P, Ollila S, Nieminen TT. PDPR gene variants predisposing to papillary thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 38062777 DOI: 10.1089/thy.2023.0560 |
0.413 |
|
| 2023 |
Hurst ZA, Liyanarachchi S, Brock P, He H, Nabhan F, Veloski C, Toland AE, Ringel MD, Jhiang SM. Presumed Pathogenic Germline and Somatic Variants in African American Thyroid Cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 38062767 DOI: 10.1089/thy.2023.0487 |
0.401 |
|
| 2023 |
Read ML, Brookes K, Zha L, Manivannan S, Kim J, Kocbiyik M, Fletcher A, Gorvin CM, Firth G, Fruhwirth GO, Nicola JP, Jhiang S, Ringel MD, Campbell MJ, Sunassee K, et al. Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37921808 DOI: 10.1158/1078-0432.CCR-23-2043 |
0.416 |
|
| 2023 |
Cooper DS, Ringel MD. A tribute to Ernest L. Mazzaferri, MD and the lasting impact that he had on thyroid cancer care ten years after his death. Endocrine. PMID 37178311 DOI: 10.1007/s12020-023-03385-9 |
0.425 |
|
| 2023 |
Khanal T, Rajan N, Li W, Liyanarachchi S, Ringel MD. The RCAN1.4 metastasis suppressor is hypermethylated at intron 1 in thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 37051697 DOI: 10.1089/thy.2022.0687 |
0.507 |
|
| 2022 |
Sipos JA, Ringel MD. Molecular testing in thyroid cancer diagnosis and management. Best Practice & Research. Clinical Endocrinology & Metabolism. 101680. PMID 35691860 DOI: 10.1016/j.beem.2022.101680 |
0.378 |
|
| 2022 |
Busaidy N, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas M, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial. Thyroid : Official Journal of the American Thyroid Association. PMID 35658604 DOI: 10.1089/thy.2022.0115 |
0.302 |
|
| 2022 |
Shonka DC, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Ahmed AH, Bible KC, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, ... ... Ringel MD, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head & Neck. PMID 35274388 DOI: 10.1002/hed.27025 |
0.429 |
|
| 2022 |
Chou R, Dana T, Haymart MR, Leung AM, Tufano R, Sosa JA, Ringel MD. Active surveillance versus thyroid surgery for differentiated thyroid cancer: A systematic review. Thyroid : Official Journal of the American Thyroid Association. PMID 35081743 DOI: 10.1089/thy.2021.0539 |
0.374 |
|
| 2021 |
Zhou W, Brumpton B, Kabil O, Gudmundsson J, Thorleifsson G, Weinstock J, Zawistowski M, Nielsen JB, Chaker L, Medici M, Teumer A, Naitza S, Sanna S, Schultheiss UT, Cappola A, ... ... Ringel MD, et al. Author Correction: GWAS of thyroid stimulating hormone highlights the pleiotropic effects and inverse association with thyroid cancer. Nature Communications. 12: 7354. PMID 34916535 DOI: 10.1038/s41467-021-27675-w |
0.393 |
|
| 2021 |
Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, ... ... Ringel MD, et al. Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers. 13. PMID 34638434 DOI: 10.3390/cancers13194950 |
0.395 |
|
| 2021 |
Ringel MD. Radioiodine: 80 years and counting; the past, present, and future. Endocrine-Related Cancer. PMID 34264856 DOI: 10.1530/ERC-21-0234 |
0.354 |
|
| 2021 |
He H, Liyanarachchi S, Li W, Comiskey DF, Yan P, Bundschuh R, Turkoglu AM, Brock P, Ringel MD, de la Chapelle A. Transcriptome analysis discloses dysregulated genes in normal appearing tumor-adjacent thyroid tissues from patients with papillary thyroid carcinoma. Scientific Reports. 11: 14126. PMID 34238982 DOI: 10.1038/s41598-021-93526-9 |
0.372 |
|
| 2021 |
Nabhan F, Dedhia PH, Ringel MD. Thyroid Cancer, Recent Advances in Diagnosis and Therapy. International Journal of Cancer. PMID 34013533 DOI: 10.1002/ijc.33690 |
0.392 |
|
| 2020 |
Saji M, Kim CS, Wang C, Zhang X, Khanal T, Coombes K, La Perle K, Cheng SY, Tsichlis PN, Ringel MD. Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model. Scientific Reports. 10: 18316. PMID 33110146 DOI: 10.1038/s41598-020-75529-0 |
0.605 |
|
| 2020 |
Ringel MD. New Horizons: Emerging Therapies and Targets in Thyroid Cancer. The Journal of Clinical Endocrinology and Metabolism. PMID 32977343 DOI: 10.1210/clinem/dgaa687 |
0.379 |
|
| 2020 |
Rajan N, Khanal T, Ringel MD. Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications. Endocrine. PMID 32779092 DOI: 10.1007/s12020-020-02453-8 |
0.423 |
|
| 2020 |
Zhou W, Brumpton B, Kabil O, Gudmundsson J, Thorleifsson G, Weinstock J, Zawistowski M, Nielsen JB, Chaker L, Medici M, Teumer A, Naitza S, Sanna S, Schultheiss UT, Cappola A, ... ... Ringel MD, et al. GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. Nature Communications. 11: 3981. PMID 32769997 DOI: 10.1038/S41467-020-17718-Z |
0.364 |
|
| 2020 |
Bautista L, Knippler CM, Ringel MD. p21-Activated Kinases in Thyroid Cancer. Endocrinology. 161. PMID 32609833 DOI: 10.1210/endocr/bqaa105 |
0.603 |
|
| 2020 |
Thies KA, Hammer AM, Hildreth BE, Steck SA, Spehar JM, Kladney RD, Geisler JM, Das M, Russell LO, Bey JF, Bolyard CM, Pilarski R, Trimboli AJ, Cuitiño MC, Koivisto CS, ... ... Ringel MD, et al. Stromal platelet-derived growth factor receptor-β signaling promotes breast cancer metastasis in the brain. Cancer Research. PMID 32327406 DOI: 10.1158/0008-5472.Can-19-3731 |
0.341 |
|
| 2020 |
Endo M, Nabhan F, Brock P, Roll K, Sipos JA, Ringel MD. MON-530 Local Lymph Node Metastasis Is Less Common in RAS- Mutated Thyroid Cancer Compared to BRAFV600E- Mutated Thyroid Cancer Journal of the Endocrine Society. 4. DOI: 10.1210/jendso/bvaa046.840 |
0.309 |
|
| 2020 |
Rajan N, Bautista L, Adik A, Ringel MD. MON-LB80 Human Thyroid Cancer Cells Are Highly Sensitive to CDK7 and 9 Inhibition Journal of the Endocrine Society. 4. DOI: 10.1210/jendso/bvaa046.2344 |
0.563 |
|
| 2020 |
Boateng I, Yilmaz AS, Brock P, Liyanarachchi S, Patel R, Walker CJ, Phay J, Chapelle Adl, Ringel M, Eisfeld A. Abstract 2073: Exome sequencing reveals PTPRS, NOTCH3, FGFR1/3 mutations as novel mutational features in medullary thyroid cancer Epidemiology. DOI: 10.1158/1538-7445.Am2020-2073 |
0.369 |
|
| 2019 |
Knippler CM, Saji M, Rajan N, Porter K, La Perle K, Ringel MD. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition. Endocrine-Related Cancer. PMID 31146260 DOI: 10.1530/ERC-19-0188 |
0.641 |
|
| 2019 |
Robb R, Yang L, Shen C, Wolfe A, Webb A, Zhang X, Vedaie M, Saji M, Jhiang SM, Ringel MD, Williams TM. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31097454 DOI: 10.1158/1078-0432.Ccr-18-3625 |
0.506 |
|
| 2019 |
Sizemore G, Hammer A, Thies K, Hildreth B, Russell L, Sizemore S, Trimboli A, Kladney R, Steck S, Das M, Bolyard C, Pilarski R, Schoenfield L, Otero J, Chakravarti A, ... Ringel M, et al. Abstract PD9-11: Platelet derived growth factor receptor-β signaling: A novel therapeutic target for breast cancer associated brain metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-11 |
0.358 |
|
| 2019 |
Thies K, Hammer A, Hildreth B, Russell L, Sizemore S, Trimboli A, Kladney R, Steck S, Das M, Bolyard C, Pilarski R, Cuitino M, Koivisto C, Schoenfield L, Otero J, ... ... Ringel M, et al. BSCI-11. STROMAL PLATELET DERIVED GROWTH FACTOR RECEPTOR-β (PDGFRβ) PROMOTES BREAST CANCER BRAIN METASTASIS Neuro-Oncology Advances. 1: i3-i3. DOI: 10.1093/noajnl/vdz014.009 |
0.302 |
|
| 2018 |
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, ... ... Ringel MD, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1429-1440. PMID 30545990 DOI: 10.6004/Jnccn.2018.0089 |
0.306 |
|
| 2018 |
Valenciaga A, Saji M, Yu L, Zhang X, Bumrah C, Yilmaz AS, Knippler CM, Miles W, Giordano TJ, Cote GJ, Ringel MD. Transcriptional targeting of oncogene addiction in medullary thyroid cancer. Jci Insight. 3. PMID 30135308 DOI: 10.1172/Jci.Insight.122225 |
0.47 |
|
| 2018 |
Thies KA, Hammer AM, Hildreth BE, Russell LO, Sizemore ST, Trimboli AJ, Kladney RD, Bolyard CM, Pilarski R, Schoenfield L, Otero J, Chakravarti A, Ringel M, Kaur B, Leone G, et al. Abstract 49: Stromal platelet derived growth factor receptor (PDGFRβ) signaling: A novel therapeutic target for breast cancer brain metastasis (BCBM) Tumor Biology. DOI: 10.1158/1538-7445.Am2018-49 |
0.392 |
|
| 2017 |
Valenciaga A, Grubbs EG, Porter K, Wakely PE, Williams MD, Cote GJ, Vasko VV, Saji M, Ringel MD. REDUCED RETINOBLASTOMA PROTEIN EXPRESSION IS ASSOCIATED WITH DECREASED PATIENT SURVIVAL IN MEDULLARY THYROID CANCER. Thyroid : Official Journal of the American Thyroid Association. PMID 29105562 DOI: 10.1089/Thy.2017.0113 |
0.456 |
|
| 2017 |
Rossfeld KK, Justiniano SE, Ding H, Gong L, Kothandaraman S, Sawant D, Saji M, Wright CL, Kirschner LS, Ringel MD, Tweedle MF, Phay JE. Biological evaluation of a novel fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model. The Journal of Clinical Endocrinology and Metabolism. PMID 28591772 DOI: 10.1210/Jc.2017-00573 |
0.354 |
|
| 2017 |
Wang C, Saji M, Justiniano SE, Yusof AM, Zhang X, Yu L, Fernández S, Wakely P, La Perle K, Nakanishi H, Pohlman N, Ringel MD. RCAN1-4 is a thyroid cancer growth and metastasis suppressor. Jci Insight. 2: e90651. PMID 28289712 DOI: 10.1172/jci.insight.90651 |
0.527 |
|
| 2017 |
Yu W, Ni Y, Saji M, Ringel MD, Jaini R, Eng C. Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells. Human Molecular Genetics. PMID 28164237 DOI: 10.1093/Hmg/Ddx037 |
0.499 |
|
| 2016 |
Ni Y, Seballos S, Fletcher B, Romigh T, Yehia L, Mester J, Senter L, Niazi F, Saji M, Ringel MD, LaFramboise T, Eng C. Germline Compound Heterozygous Poly-glutamine Deletion in USF3 May Be Involved in Predisposition to Heritable and Sporadic Epithelial Thyroid Carcinoma. Human Molecular Genetics. PMID 28011713 DOI: 10.1093/Hmg/Ddw382 |
0.527 |
|
| 2016 |
Nabhan F, Ringel MD. Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocrine-Related Cancer. PMID 27965276 DOI: 10.1530/ERC-16-0432 |
0.376 |
|
| 2016 |
Justiniano SE, McElroy JP, Yu L, Yilmaz AS, Coombes KR, Senter L, Nagy R, Wakely P, Volinia S, Vinco M, Giordano TJ, Croce CM, Saji M, Ringel MD. Genetic variants in thyroid cancer distant metastases. Endocrine-Related Cancer. PMID 27542854 DOI: 10.1530/Erc-16-0351 |
0.355 |
|
| 2016 |
Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos R, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang SM. Risk Factors of (131)I-Induced Salivary Gland Damage in Thyroid Cancer Patients. The Journal of Clinical Endocrinology and Metabolism. jc20161605. PMID 27533304 DOI: 10.1210/Jc.2016-1605 |
0.351 |
|
| 2016 |
Jendrzejewski JP, Liyanarachchi S, Nagy R, Senter L, Wakely PE, Thomas A, Nabhan F, He H, Li W, Sworczak K, Ringel MD, Kirschner LS, de la Chapelle A. Papillary thyroid carcinoma: Association between germline DNA variant markers and clinical parameters. Thyroid : Official Journal of the American Thyroid Association. PMID 27342578 DOI: 10.1089/Thy.2015.0665 |
0.3 |
|
| 2016 |
Wang Y, Li W, Phay JE, Shen R, Pellegata N, Saji M, Ringel MD, de la Chapelle A, He H. Primary cell culture systems for human thyroid studies. Thyroid : Official Journal of the American Thyroid Association. PMID 27296473 DOI: 10.1089/Thy.2015.0518 |
0.364 |
|
| 2015 |
Shirley LA, McCarty S, Yang MC, Saji M, Zhang X, Phay J, Ringel MD, Chen CS. Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. Surgery. PMID 26549818 DOI: 10.1016/J.Surg.2015.10.016 |
0.789 |
|
| 2015 |
Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, ... ... Ringel MD, et al. Anaplastic Thyroid Carcinoma, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1140-50. PMID 26358798 DOI: 10.6004/Jnccn.2015.0139 |
0.321 |
|
| 2015 |
Agarwal K, Saji M, Lazaroff SM, Palmer AF, Ringel MD, Paulaitis ME. Analysis of exosome release as a cellular response to MAPK pathway inhibition. Langmuir : the Acs Journal of Surfaces and Colloids. 31: 5440-8. PMID 25915504 DOI: 10.1021/Acs.Langmuir.5B00095 |
0.334 |
|
| 2015 |
Plews RL, Mohd Yusof A, Wang C, Saji M, Zhang X, Chen CS, Ringel MD, Phay JE. A Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell Growth. The Journal of Clinical Endocrinology and Metabolism. 100: E748-56. PMID 25710562 DOI: 10.1210/jc.2014-1777 |
0.601 |
|
| 2015 |
Ni Y, Seballos S, Ganapathi S, Gurin D, Fletcher B, Ngeow J, Nagy R, Kloos RT, Ringel MD, LaFramboise T, Eng C. Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. Endocrine-Related Cancer. 22: 121-30. PMID 25694510 DOI: 10.1530/Erc-14-0537 |
0.41 |
|
| 2015 |
Nagy R, Ringel MD. Genetic predisposition for nonmedullary thyroid cancer. Hormones & Cancer. 6: 13-20. PMID 25338077 DOI: 10.1007/s12672-014-0205-y |
0.396 |
|
| 2014 |
Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, ... ... Ringel MD, et al. Thyroid carcinoma, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1671-80; quiz 1680. PMID 25505208 DOI: 10.6004/Jnccn.2014.0169 |
0.398 |
|
| 2014 |
McCarty SK, Saji M, Zhang X, Knippler CM, Kirschner LS, Fernandez S, Ringel MD. BRAF activates and physically interacts with PAK to regulate cell motility. Endocrine-Related Cancer. 21: 865-77. PMID 25228413 DOI: 10.1530/Erc-14-0424 |
0.794 |
|
| 2014 |
Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, Kirschner JM, Parlow AF, Saji M, Jarjoura D, Ringel MD, La Perle KM, Kirschner LS. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. The Journal of Clinical Endocrinology and Metabolism. 99: E804-12. PMID 24512487 DOI: 10.1210/jc.2013-3101 |
0.516 |
|
| 2014 |
Lakshmanan A, Doseff AI, Ringel MD, Saji M, Rousset B, Zhang X, Jhiang SM. Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells. Thyroid : Official Journal of the American Thyroid Association. 24: 878-87. PMID 24400871 DOI: 10.1089/Thy.2013.0614 |
0.444 |
|
| 2013 |
Phay JE, Ringel MD. Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocrine-Related Cancer. 20: R307-19. PMID 24036131 DOI: 10.1530/ERC-13-0187 |
0.469 |
|
| 2013 |
Ding H, Yusof AM, Kothandaraman S, Saji M, Wang C, Kumar K, Milum K, Carleton M, Pan X, Ringel MD, Tweedle MF, Phay JE. Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 98: E1722-9. PMID 24030941 DOI: 10.1210/Jc.2013-1756 |
0.358 |
|
| 2013 |
Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MD. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. The Journal of Clinical Endocrinology and Metabolism. 98: E1314-22. PMID 23709653 DOI: 10.1210/Jc.2012-3937 |
0.783 |
|
| 2012 |
Liu YY, Zhang X, Ringel MD, Jhiang SM. Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells. Endocrine-Related Cancer. 19: 291-304. PMID 22355179 DOI: 10.1530/Erc-11-0288 |
0.435 |
|
| 2012 |
Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, Jonasdottir A, Sigurdsson A, Stacey SN, Johannsdottir H, Helgadottir HT, Li W, Nagy R, Ringel MD, Kloos RT, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nature Genetics. 44: 319-22. PMID 22267200 DOI: 10.1038/Ng.1046 |
0.364 |
|
| 2012 |
Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M, Ringel MD. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocrine-Related Cancer. 19: 29-38. PMID 22109971 DOI: 10.1530/Erc-11-0155 |
0.755 |
|
| 2012 |
Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, Ringel MD, Eng C. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Human Molecular Genetics. 21: 300-10. PMID 21979946 DOI: 10.1093/Hmg/Ddr459 |
0.404 |
|
| 2011 |
Jendrzejewski J, Tomsic J, Lozanski G, Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT, Heerema NA, de la Chapelle A. Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 96: E1876-80. PMID 21900378 DOI: 10.1210/jc.2011-1643 |
0.302 |
|
| 2011 |
Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY, Ringel MD. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene. 30: 4307-15. PMID 21532616 DOI: 10.1038/Onc.2011.136 |
0.751 |
|
| 2011 |
Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, ... ... Ringel MD, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2357-63. PMID 21519026 DOI: 10.1200/JCO.2010.33.9473 |
0.431 |
|
| 2011 |
Ringel MD. Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid : Official Journal of the American Thyroid Association. 21: 487-92. PMID 21476892 DOI: 10.1089/thy.2011.2121 |
0.532 |
|
| 2011 |
Ringel MD. Linking oncogenes to invasion in thyroid cancer. Cell Cycle (Georgetown, Tex.). 10: 737-8. PMID 21325890 |
0.521 |
|
| 2010 |
McCarty SK, Saji M, Zhang X, Jarjoura D, Fusco A, Vasko VV, Ringel MD. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion Endocrine-Related Cancer. 17: 989-999. PMID 20817787 DOI: 10.1677/Erc-10-0168 |
0.793 |
|
| 2010 |
Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, Ringel MD. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. The Journal of Clinical Endocrinology and Metabolism. 95: 4244-50. PMID 20519347 DOI: 10.1210/jc.2010-0440 |
0.334 |
|
| 2010 |
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2323-30. PMID 20368568 DOI: 10.1200/Jco.2009.25.0068 |
0.427 |
|
| 2010 |
Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors Molecular and Cellular Endocrinology. 321: 20-28. PMID 19897009 DOI: 10.1016/j.mce.2009.10.016 |
0.548 |
|
| 2009 |
Cheng SY, Ringel MD. Frontiers in thyroid cancer: December 2009 Thyroid. 19: 1297-1298. PMID 20001712 DOI: 10.1089/thy.2009.1612 |
0.48 |
|
| 2009 |
Ringel MD. Molecular markers of aggressiveness of thyroid cancer. Current Opinion in Endocrinology, Diabetes, and Obesity. 16: 361-6. PMID 19584719 DOI: 10.1097/MED.0b013e32832ff2cb |
0.389 |
|
| 2009 |
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid : Official Journal of the American Thyroid Association. 19: 565-612. PMID 19469690 DOI: 10.1089/Thy.2008.0403 |
0.381 |
|
| 2009 |
Nadella KS, Saji M, Jacob NK, Pavel E, Ringel MD, Kirschner LS. Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1 Embo Reports. 10: 599-605. PMID 19424295 DOI: 10.1038/embor.2009.58 |
0.379 |
|
| 2009 |
Espinosa AV, Shinohara M, Porchia LM, Chung YJ, McCarty S, Saji M, Ringel MD. Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clinical & Experimental Metastasis. 26: 517-26. PMID 19306109 DOI: 10.1007/S10585-009-9251-1 |
0.78 |
|
| 2009 |
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, et al. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1675-84. PMID 19255327 DOI: 10.1200/Jco.2008.18.2717 |
0.354 |
|
| 2009 |
Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 94: 164-70. PMID 18854394 DOI: 10.1210/jc.2008-1631 |
0.459 |
|
| 2009 |
South CD, Baker MJ, Phelps MA, Ringel M, Patel T, Bekaii-Saab T. W1771 Phospho-ERK Expression As a Predictor of Therapeutic Response to MEK-1/2 Inhibitors in Biliary Tract Cancers Gastroenterology. 136: A-858. DOI: 10.1016/S0016-5085(09)63957-3 |
0.523 |
|
| 2008 |
Ringel MD. "Thyroid cancer" cell line misidentification: a time for proactive change. The Journal of Clinical Endocrinology and Metabolism. 93: 4226-7. PMID 18987282 DOI: 10.1210/jc.2008-2008 |
0.486 |
|
| 2008 |
Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America. 37: 375-87, viii-ix. PMID 18502332 DOI: 10.1016/j.ecl.2008.01.001 |
0.502 |
|
| 2007 |
Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS, Ringel MD. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Molecular Pharmacology. 72: 1124-31. PMID 17673571 DOI: 10.1124/Mol.107.037556 |
0.56 |
|
| 2007 |
Mody M, Dharker N, Bloomston M, Wang PS, Chou FS, Glickman TS, McCaffrey T, Yang Z, Pumfery A, Lee D, Ringel MD, Pinzone JJ. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocrine-Related Cancer. 14: 305-15. PMID 17639046 DOI: 10.1677/Erc-06-0003 |
0.407 |
|
| 2007 |
Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proceedings of the National Academy of Sciences of the United States of America. 104: 2803-8. PMID 17296934 DOI: 10.1073/pnas.0610733104 |
0.49 |
|
| 2007 |
Ringel MD. Can ultrasound and clinical features be used to predict thyroid cancer in solitary nodules and multinodular goiter? Nature Clinical Practice. Endocrinology & Metabolism. 3: 334-5. PMID 17290235 DOI: 10.1038/ncpendmet0451 |
0.363 |
|
| 2007 |
Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. British Journal of Cancer. 96: 16-20. PMID 17179987 DOI: 10.1038/sj.bjc.6603520 |
0.535 |
|
| 2007 |
Shinohara M, Yun JC, Saji M, Ringel MD. Minireview: AKT in thyroid tumorigenesis and progression Endocrinology. 148: 942-947. PMID 16946008 DOI: 10.1210/en.2006-0937 |
0.611 |
|
| 2007 |
Espinosa AV, Porchia L, Ringel MD. Erratum: Targeting BRAF in thyroid cancer British Journal of Cancer. 96: 1313-1313. DOI: 10.1038/sj.bjc.6603676 |
0.465 |
|
| 2006 |
Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 91: 2201-4. PMID 16522694 DOI: 10.1210/jc.2005-2498 |
0.317 |
|
| 2006 |
Kloos R, Ringel M, Knopp M, Heverhagen J, Rittenberry J, Weldy L, Arbogast D, Collamore M, King M, Young D, Shah M. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43–9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study Journal of Clinical Oncology. 24: 5534-5534. DOI: 10.1200/Jco.2006.24.18_Suppl.5534 |
0.373 |
|
| 2006 |
Droz J, Baudin E, Medvedev V, Delord J, Kane M, Kloos R, Ringel M, Kahatt C, Weems G, Shah M. Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: Phase II international multicenter study (preliminary results) Journal of Clinical Oncology. 24: 15511-15511. DOI: 10.1200/Jco.2006.24.18_Suppl.15511 |
0.357 |
|
| 2006 |
Al-Saif OH, Farrar WB, Bloomston MB, Ringel MD, Kloos RT. S075 Aggressive Detection and Resection of Recurrent or Persistent I 131–Resistant Papillary Thyroid Cancer Archives of Otolaryngology–Head & Neck Surgery. 132: 855. DOI: 10.1001/ARCHOTOL.132.8.855-B |
0.362 |
|
| 2005 |
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, ... ... Ringel MD, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 90: 6373-9. PMID 16174717 DOI: 10.1210/jc.2005-0987 |
0.412 |
|
| 2005 |
Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, Ringel MD. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma Endocrinology. 146: 4456-4463. PMID 16002527 DOI: 10.1210/en.2005-0172 |
0.608 |
|
| 2005 |
Stathatos N, Bourdeau I, Espinosa AV, Saji M, Vasko VV, Burman KD, Stratakis CA, Ringel MD. KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. The Journal of Clinical Endocrinology and Metabolism. 90: 5432-40. PMID 15998767 DOI: 10.1210/jc.2005-0963 |
0.378 |
|
| 2005 |
Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence Biochemical and Biophysical Research Communications. 332: 167-173. PMID 15896313 DOI: 10.1016/j.bbrc.2005.04.109 |
0.367 |
|
| 2005 |
Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. The Journal of Clinical Endocrinology and Metabolism. 90: 2512-21. PMID 15713710 DOI: 10.1210/Jc.2004-2028 |
0.309 |
|
| 2005 |
Harii N, Lewis CJ, Vasko V, McCall K, Benavides-Peralta U, Sun X, Ringel MD, Saji M, Giuliani C, Napolitano G, Goetz DJ, Kohn LD. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Molecular Endocrinology (Baltimore, Md.). 19: 1231-50. PMID 15661832 DOI: 10.1210/Me.2004-0100 |
0.3 |
|
| 2004 |
Ringel MD. Diagnostic molecular markers in thyroid cancer. Cancer Treatment and Research. 122: 295-316. PMID 16209052 |
0.413 |
|
| 2004 |
Kada F, Saji M, Ringel MD. AKT: A potential target for thyroid cancer therapy Current Drug Targets: Immune, Endocrine and Metabolic Disorders. 4: 181-185. PMID 15379721 DOI: 10.2174/1568008043339857 |
0.583 |
|
| 2004 |
Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells Molecular Carcinogenesis. 41: 98-107. PMID 15378648 DOI: 10.1002/Mc.20042 |
0.51 |
|
| 2004 |
Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M, Ringel MD. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels Journal of Clinical Endocrinology and Metabolism. 89: 2982-2988. PMID 15181088 DOI: 10.1210/jc.2003-031767 |
0.571 |
|
| 2004 |
Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocrine-Related Cancer. 11: 97-116. PMID 15027888 DOI: 10.1677/ERC.0.0110097 |
0.305 |
|
| 2004 |
Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D. BRAF T1796A transversion mutation in various thyroid neoplasms. The Journal of Clinical Endocrinology and Metabolism. 89: 1365-8. PMID 15001635 DOI: 10.1210/JC.2003-031488 |
0.315 |
|
| 2004 |
Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. Journal of Medical Genetics. 41: 161-70. PMID 14985374 DOI: 10.1136/jmg.2003.015339 |
0.642 |
|
| 2004 |
Ringel MD. Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. The Journal of Clinical Endocrinology and Metabolism. 89: 29-32. PMID 14715823 DOI: 10.1210/jc.2003-031956 |
0.308 |
|
| 2004 |
Saji M, Ringel MD. Akt signaling in thyroid neoplasia Current Opinion in Endocrinology and Diabetes. 11: 197-204. DOI: 10.1097/01.med.0000137757.50167.ec |
0.587 |
|
| 2003 |
Stabile E, Zhou YF, Saji M, Castagna M, Shou M, Kinnaird TD, Baffour R, Ringel MD, Epstein SE, Fuchs S. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circulation Research. 93: 1059-65. PMID 14605018 DOI: 10.1161/01.RES.0000105086.31909.1B |
0.388 |
|
| 2003 |
Ramljak D, Coticchia CM, Nishanian TG, Saji M, Ringel MD, Conzen SD, Dickson RB. Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Experimental Cell Research. 287: 397-410. PMID 12837294 DOI: 10.1016/S0014-4827(03)00135-6 |
0.364 |
|
| 2003 |
Grammatopoulos D, Elliott Y, Smith SC, Brown I, Grieve RJ, Hillhouse EW, Levine MA, Ringel MD. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. Molecular Pathology : Mp. 56: 162-6. PMID 12782763 DOI: 10.1136/mp.56.3.162 |
0.341 |
|
| 2003 |
Braga-Basaria M, Ringel MD. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 88: 1947-60. PMID 12727938 DOI: 10.1210/jc.2002-021863 |
0.492 |
|
| 2002 |
Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid : Official Journal of the American Thyroid Association. 12: 953-61. PMID 12490072 DOI: 10.1089/105072502320908286 |
0.351 |
|
| 2002 |
Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. The Journal of Clinical Endocrinology and Metabolism. 87: 4792-6. PMID 12364475 DOI: 10.1210/jc.2002-020390 |
0.408 |
|
| 2002 |
Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells Journal of Clinical Endocrinology and Metabolism. 87: 2399-2402. PMID 11994395 DOI: 10.1210/jc.87.5.2399 |
0.456 |
|
| 2001 |
Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid : Official Journal of the American Thyroid Association. 11: 339-51. PMID 11349832 DOI: 10.1089/10507250152039073 |
0.365 |
|
| 2001 |
Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD, Tuttle RM. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 14: 289-96. PMID 11301345 DOI: 10.1038/modpathol.3880305 |
0.402 |
|
| 2000 |
Ringel MD, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman KD. Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells Thyroid. 10: 865-869. PMID 11081253 DOI: 10.1089/THY.2000.10.865 |
0.458 |
|
| 2000 |
Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, Sparling YH, Wartofsky L, Sessions RB, Ringel MD. Prognostic importance of vascular invasion in papillary thyroid carcinoma. Archives of Otolaryngology--Head & Neck Surgery. 126: 309-12. PMID 10722002 DOI: 10.1001/ARCHOTOL.126.3.309 |
0.393 |
|
| 1999 |
Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. The Journal of Clinical Endocrinology and Metabolism. 83: 4435-42. PMID 9851791 DOI: 10.1210/JCEM.83.12.5346 |
0.334 |
|
| 1998 |
Ringel MD, Saji M, Schwindinger WF, Segev D, Zeiger MA, Levine MA. Absence of activating mutations of the genes encoding the α-subunits of G11 and G(q) in thyroid neoplasia Journal of Clinical Endocrinology and Metabolism. 83: 554-559. PMID 9467574 DOI: 10.1210/Jcem.83.2.4536 |
0.301 |
|
| 1997 |
Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinology and Metabolism Clinics of North America. 25: 49-68. PMID 8907680 DOI: 10.1016/S0889-8529(05)70312-1 |
0.363 |
|
| 1996 |
Ringel MD, Ladenson PW. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. The Journal of Clinical Endocrinology and Metabolism. 81: 1724-5. PMID 8626823 DOI: 10.1210/JCEM.81.5.8626823 |
0.356 |
|
| Show low-probability matches. |